Evidence map›Paper›PMID 26191952›Full record

Trial reportBone marrow transplantation2016

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.

Yeohan Song, John Magenau, Yumeng Li, Thomas Braun, Lawrence Chang, Dale Bixby, David A Hanauer, Komal A Chughtai, Erin Gatza, Daniel Couriel and 11 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDTransplantation and cellular therapy · 2024
    Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Yeohan Song *University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
John Magenau *Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Yumeng LiSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
Thomas BraunSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
Lawrence ChangDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
Dale BixbyDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
David A HanauerComprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Komal A ChughtaiUniversity of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
Erin GatzaDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
Daniel CourielDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Steven GoldsteinDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Attaphol PawarodeDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Pavan ReddyDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Mary RiwesDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
James ConnellyComprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Andrew HarrisComprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Carrie KitkoComprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
John LevineComprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Greg YanikComprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Brian Parkin *Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Sung Won Choi *Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Michigan Center for Translational Pathology · USUniversity of Michigan–Ann Arbor · US

Funding

Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHDK23AI091623 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHOI, SUNG WON · 2011 to 2015
$658k
NIAID NIH HHS 1K23AI091623NIAID NIH HHS K23 AI091623
6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) has been increasingly used in the setting of FMS-like tyrosine kinase-3 (FLT3)-mutated AML. However, its role in conferring durable relapse-free intervals remains in question. Herein we sought to investigate FLT3 mutational status on transplant outcomes. We conducted a retrospective cohort study of 262 consecutive AML patients who underwent first-time allogeneic HCT (2008-2014), of whom 171 had undergone FLT3-ITD (internal tandem duplication) mutational testing. FLT3-mutated AML was associated with nearly twice the relapse risk (RR) compared with those without FLT3 mutation 3 years post-HCT (63% vs 37%, P<0.001) and with a shorter median time to relapse (100 vs 121 days). FLT3 mutational status remained significantly associated with this outcome after controlling for patient, disease and transplant-related risk factors (P<0.05). Multivariate analysis showed a significant association of FLT3 mutation with increased 3-year RR (hazard ratio (HR) 3.63, 95% confidence interval (CI): 2.13, 6.19, P<0.001) and inferior disease-free survival (HR 2.05, 95% CI: 1.29, 3.27, P<0.01) and overall survival (HR 1.92, 95% CI: 1.14, 3.24, P<0.05). These data demonstrate high risk of early relapse after allogeneic HCT for FLT3-mutated AML that translates into adverse disease-free and overall survival outcomes. Additional targeted and coordinated interventions are needed to maintain durable remission after allogeneic HCT in this high-risk population.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMutationAdolescentAdultAgedAllograftsChildChild, PreschoolDisease-Free SurvivalFemalefms-Like Tyrosine Kinase 3HumansInfantMaleMiddle AgedFLT3 protein, humanfms-Like Tyrosine Kinase 3

Identifiers

PMID26191952
PMCPMC4720584
OpenAlexW1569493950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.